A Phase 1 Clinical Trial of Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Disease Name: 
Non-Hodgkin Lymphoma
Study Status: 
Date: 
July 18, 2024